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Lupus Nephropathy S47without affecting autoantibody profile, splenic lymphocytes and
macrophages.Table 1. Baseline clinical features of LN patients with class III and III+V.
III III＋V P value
Patients (n) 207 169
Female (n, %) 186 (89.9%) 146 (86.4%) 0.335
LN onset age (years) 30.98.3 30.18.1 0.371
Mean arterial pressure
(mmHg)
95.513.2 99.213.7 0.008
Haemoglobin (g/dl) a 10.52.1 10.92.3 0.053
Haematuria (104cells/ml) 36.0 (3.0-150.0) 11.0 (2.0-50.0) 0.397
24-h urinary protein (g/24h) 1.661.99 3.162.72 <0.001
Serum creatinine (mg/dl) a 0.910.50 0.900.81 0.890
Serum complement C3 (g/L) 0.5980.260 0.6370.287 0.182
Serum complement C4 (g/L) 0.1560.126 0.1670.132 0.401
a Conversion factors for units: serum creatinine in mg/dl to mmol/l,
88.4; haemoglobin in g/dl to g/l, 0.1.
Table 2. Baseline clinical features of LN patients with class IV and IV+V.
IV IV＋V P value
Patients (n, %) 559 233
Female (n, %) 493 (88.2%) 202 (86.7%) 0.554
LN onset age (years) 31.08.4 30.28.9 0.220
Mean arterial pressure
(mmHg)
101.214.5 100.212.5 0.350
Haemoglobin (g/dl) a 8.92.0 9.32.1＃ 0.018
Haematuria (104cells/ml) 90.0
(15.0-265.0)
60.0
(12.0-187.5)
0.012
24-h urinary protein (g/24h) 3.412.92 4.193.10 <0.001
Serum creatinine (mg/dl) a 1.481.33 1.341.21 0.077
Serum complement C3 (g/L) 0.5050.269 0.4860.230 0.382http://dx.doi.org/10.1016/j.hkjn.2015.08.129
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Objectives: To investigate the clinical characteristics and outcomes of lupus
podocytopathy with different glomerular lesions.
Methods: Lupus podocytopathy (defined as foot process effacement 50% of
the glomerular capillary loop area without deposits in capillary wall under
electron microscopy) was screened from 3750 lupus nephritis patients in
Nanjing Jinling hospital between January 2000 and December 2013 and
were divided into 3 groups including minimal change disease (MCD), mesan-
gial proliferation (MP) and focal segmental glomerulosclerosis (FSGS) by light
microscopy. The clinical characteristics, treatment response and outcomes
were retrospectively studied and compared among 3 groups.
Results: 53 patients (1.41%) were re-classified as lupus podocytopathy,
including 13 with MCD, 31 with MP and 9 with FSGS. 50 (94.3%) patients pre-
sented with nephrotic syndrome, 3 (5.7%) patients showed non-nephrotic
proteinuria, 17 (32.1%) patients had concomitant AKI. The incidence of AKI
was significantly higher in FSGS group (77.8%) than in MCD (23.1%) and MP
(22.6%) groups (P< 0.01). Low serum C3 was more frequently seen in FSGS
(88.9%) and MP groups (83.9%) than in MCD group (23.1%, P< 0.05). No dif-
ference was observed in foot process effacement among the 3 groups.
More patients had severe acute tubulointerstitial lesions in FSGS group
(77.8%) than in MCD (7.7%) and MP (22.6%) groups (P< 0.01). 50 (94.3%) pa-
tients achieved remission after immunosuppressive induction treatment,
among whom 41 (77.4%) had complete remission (CR). The CR rate in FSGS
group (22.2%) was significantly lower than in MCD (92.3%) and MP (87.1%)
groups (P< 0.01). During follow-up for 44 months (9e125 months), 29
(54.7%) patients had renal relapse, no patient died or developed end stage
renal disease.
Conclusion: Lupus podocytopathy with different glomerular lesions showed
variable clinical characteristics with benign outcomes. Patients with MCD
and MP shared similar clinical features, which were different from patients
with FSGS in terms of AKI incidence, tubular injury severity and response to
immunosuppressive treatment.Serum complement C4 (g/L) 0.1450.124 0.1340.104 0.278
a Conversion factors for units: serum creatinine in mg/dl to mmol/l,
88.4; haemoglobin in g/dl to g/l, 0.1.
Table 3. Baseline clinical features of LN patients with subclass IV-S and
IV-G.
IV-S IV-G P value
Patients (n, %) 117 (20.9%) 442 (79.1%)
Female (n, %) 104 (88.9%) 389 (88.0%) 0.873
LN onset age (years) 32.28.2 30.88.4 0.108
Mean arterial pressure
(mmHg)
98.013.0 102.114.8 0.004
Haemoglobin (g/dl) a 9.21.9 8.82.0 0.124
Haematuria (104cells/ml) 60.0
(10.5-244.0)
100.0
(15.0-271.3)
0.419
24-h urinary protein (g/24h) 2.751.76 3.593.13 <0.001
Serum creatinine (mg/dl) a 1.361.30 1.511.33 0.254
Serum complement C3 (g/L) 0.5970.297 0.4810.256 <0.001
Serum complement C4 (g/L) 0.1630.123 0.1400.123 0.071
ANCA positive rate (％) 9.5% 5.2% 0.130
a Conversion factors for units: serum creatinine in mg/dl to mmol/l,
88.4; haemoglobin in g/dl to g/l, 0.1.http://dx.doi.org/10.1016/j.hkjn.2015.08.130
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Objective: To observe the discrepancy between class III and class III+V, be-
tween class IV and class IV+V, and between subclass IV-S and IV-G on clinico-
pathological features and renal outcomes and explore the pathological
lesions associated with poor renal outcomes in patients with different
classes.
Methods: The records of all adult patients with biopsy-proven proliferative
lupus nephritis followed for at least 1 year were reviewed. All patients
were pathologically classified according to the 2003 ISN/RPS classification
of lupus nephritis and each pathological lesion was semiquantatively scored.
Results: Patients with class III+V (class IV+V) presented with more severe
proteinuria and chronic pathological lesions and milder acute pathological
lesions than patients with class III (class IV) (Tables 1e2, 4e5); patients
with subclass IV-G presented with more severe hypertension, proteinuriaand hypocomplementemia, lower ANCA positivity rate, more severe glomer-
ular cell proliferation and hyaline deposit, and milder fibrinoid necrosis and
crescent than patients with subclass IV-S (Tables 3, 6). The renal outcomes
between patients with class III and class III+V, between class IV and class
IV+V, and between subclass IV-S and subclass IV-G were not different respec-
tively (Figures 1e3). Global glomerulosclerosis, cellular crescent, fibrous
crescent, glomerular cell proliferation, tubular acute injury, interstitial
inflammation and TMA were predictors for ESRD.
Table4. Baselinepathological features ofLNpatientswith class III and III＋V.
III III＋V P value
Glbal glomerulosclerosis (n, %) 0.011
0 118 (57.0%) 81 (47.9%)
1 76 (36.7%) 70 (41.4%)
2 11 (5.3%) 12 (7.1%)
3 2 (1.0%) 6 (3.6%)
Segmental glomerulosclerosis (n, %) 0.002
0 160 (77.3%) 92 (54.4%)
1 45 (21.7%) 73 (43.2%)
2 2 (1.0%) 3 (1.8%)
3 0 (0%) 1 (0.6%)
Cellular crescent (n, %) 0.017
0 73 (35.3%) 71 (42.0%)
1 117 (56.5%) 92 (54.4%)
2 17 (8.2%) 6 (3.6%)
3 0 (0%) 0 (0%)
Fibrinoid necrosis (n, %) 0.003
0 145 (70.0%) 141 (83.4%)
1 60 (29.0%) 27 (16.0%)
2 2 (1.0%) 1 (0.6%)
Hyaline deposit (n, %) 0.028
0 165 (79.7%) 149 (88.2%)
1 40 (19.3%) 19 (11.2%)
2 2 (1.0%) 1 (0.6%)
3 0 (0%) 0 (0％)
Tubular atrophy/
interstitial fibrosis (n, %)
0.015
0 74 (35.7%) 45 (26.6%)
1 122 (58.9%) 101 (59.8%)
2 10 (4.8%) 20 (11.8%)
3 1 (0.5%) 3 (1.8%)
Atherosclerosis (n, %) 0.039
0 143 (69.1%) 96 (56.8%)
1 18 (8.7%) 30 (17.8%)
2 46 (22.2%) 43 (25.4%)
Table5.Baselinepathological featuresof LNpatientswithclass IVand IV＋V.
IV IV＋V P value
Cellular crescent (n, %) 0.008
0 104 (18.6%) 55 (23.6%)
1 257 (46.0%) 115 (49.4%)
2 148 (26.5%) 50 (21.5%)
3 50 (8.9%) 13 (5.6%)
Fibrinoid necrosis (n, %) 0.002
0 340 (60.8%) 168 (72.1%)
1 217 (38.8%) 65 (27.9%)
2 2 (0.4%) 0 (0％)
Tubular atrophy/
interstitial fibrosis (n, %)
0.024
0 202 (36.1％) 54 (23.2%)
1 274 (49.0%) 139 (59.7%)
2 77 (13.8%) 39 (16.7%)
3 6 (1.1%) 1 (0.4%)
Table 6. Baseline pathological features of LN patients with subclass IV-S
and IV-G.
IV-S IV-G P value
Segmental glomerulosclerosis (n, %) <0.001
0 67 (57.3%) 395 (89.4%)
1 42 (35.9%) 43 (9.7%)
2 8 (6.8%) 4 (0.9%)
3 0 (0%) 0 (0%)
Cellular crescent (n, %) <0.001
0 7 (6.0%) 97 (21.9%)
1 48 (41.0%) 209 (47.3%)
2 44 (37.6%) 104 (23.5%)
3 18 (15.4%) 32 (7.2%)
Fibrous crescent (n, %) <0.001
0 73 (62.4%) 378 (85.5%)
Table 6 (continued )
IV-S IV-G P value
1 39 (33.3%) 64 (14.5%)
2 5 (4.3%) 0 (0%)
3 0 (0%) 0 (0%)
Glomerular cell proliferation (n, %) <0.001
0 13 (11.1%) 3 (0.7%)
1 50 (42.7%) 19 (4.3%)
2 37 (31.6%) 51 (11.5%)
3 17 (14.5%) 369 (83.5%)
Leucocyte exudation (n, %) <0.001
0 47 (40.2%) 113 (25.6%)
1 49 (41.9%) 160 (36.2%)
2 16 (13.7%) 89 (20.1%)
3 5 (4.3%) 80 (18.1%)
Karyorrhexis (n, %) 0.045
0 50 (42.7%) 235 (53.2%)
1 67 (57.3%) 207 (46.8%)
Fibrinoid necrosis (n, %) 0.004
0 58 (49.6%) 282 (63.8%)
1 57 (48.7%) 160 (36.2%)
2 2 (1.7%) 0 (0%)
Hyaline deposit (n, %) <0.001
0 83 (70.9%) 117 (26.5%)
1 21 (17.9%) 144 (32.6%)
2 12 (10.3%) 101 (22.9%)
3 1 (0.9%) 80 (18.1%)
Tubular atrophy/
interstitial fibrosis (n, %)
0.048
0 34 (29.1%) 168 (38.0%)
1 57 (48.7%) 217 (49.1%)
2 25 (21.4%) 52 (11.8%)
3 1 (0.9%) 5 (1.1%)
Tubular acute injury (n, %) 0.001
0 26 (22.2%) 91 (20.6%)
1 76 (65.0%) 229 (51.8%)
2 15 (12.8%) 120 (27.1%)
3 0 (0%) 2 (0.5%)
Noninflammatory necrotizing
vasculopathy (n, %)
<0.001
0 117 (100%) 395 (89.4%)
1 0 (0%) 47 (10.6%)
S48 Lupus NephropathyFigure 1. Renal survival rates of LN patients with class III and III+V (The 5-, 10-,
and 20-year renal survival rates of patients with class III were 94.6%, 92.1% and
72.2%, respectively; with class III+V, 93.9%, 91.5% and 88.9%, respectively).
Lupus Nephropathy S49Figure 2. Renal survival rates of LN patients with class IV and IV+V (The 5-, 10-,
and 20-year renal survival rates of patients with class IV were 89.1%, 82.7% and
60.3%, respectively; with class IV+V, 90.8%, 82.7%, and 54.7%, respectively).Figure 3. Renal survival rates of LN patients with subclass IV-S and IV-G (The
5-, 10-, and 20-year renal survival rates of patients with subclass IV-S were
91.6%, 86.2% and 69.6%, respectively; with subclass IV-G, 88.4%, 81.9% and
58.9%, respectively).
Conclusion: LN patients with proliferative lesions combined with membra-
nous lesions presented with both clinicopathological characteristics of the
two types of lesions, but their renal outcomes were not different from pa-
tients with pure proliferative lesions. Patients with subclass IV-S and subclass
IV-G LN had their own clinicopathological characteristics respectively, but the
division of class IV into the two subclasses was not meaningful for predicting
renal outcomes. In addition to glomerular lesions, tubulointerstitial and
vascular lesions were also predictors for poor renal outcomes.http://dx.doi.org/10.1016/j.hkjn.2015.08.1310068
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Objective: To observe and analyze the clinical manifestations and prognosis
of systemic lupus erythematosus (SLE) complicated with intestinal pseudo-
obstruction (IPO).
Methods: From January 2004 to April 2014, 30 patients with SLE and IPO
were enrolled to analysis the clinical manifestations, laboratory tests, imag-
ing characteristics, treatment and prognosis.
Results: They were 26 females and 4 males, with mean age 26.1  11.2
years old. The median history of SLE was 27.5 months. The SLE-DAI score
was 11.2  7.4 when IPO occurred. 6 patients had identified induction fac-
tors (5 cases had unclean food, 1 case had respiratory tract infection). The
most common manifestions of IPO were nausea and vomiting (76.6%),
abdominal pain (66.7%), diarrhea (56.7%), bloating (30%). More than 75%
patients showed intestinal obstruction in KUB and abdominal CT. 7 patients
with hydronephrosis and h^ydroureters concomitantly. Most cases had ane-
mia (96.7%). 6 patients had thrombocytopenia and 8 patients had leuko-
penia. The direct Coomb’s tests were positive in 4 cases. All patients had
hypocomplementemia, with positive autoantidodies of ds_DNA (51.7%),
anticardiolipin antibody (30.4%), lupus anticoagulant (43.8%) and anti-
C1q antibody (47.4%). 29 patients were treated with aggressive immuno-
suppressive therapy, 10 patients received methylprednisolone plus
(0.75e3.00 g), 11 patients received gamma immunoglobulin therapy
(15e100 g). 29 patients were improved after therapy. The median remis-
sion time of IPO was 12 days (8e19 days). There were 24 patients fol-
lowed-up for 1e60 months; 2 died of complications, 5 patients had
relapse of IPO, 4 cases entered ESRD. Patients had stable condition of
lupus.
Conclusion: SLE complicated with IPO is relatively rare in clinical. The mani-
festation is diversity and easily missed diagnose or misdiagnosis. Early diag-
nosis and timely immunosuppressive therapy could improve the prognosis.http://dx.doi.org/10.1016/j.hkjn.2015.08.132
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Objective: The dosages of mycophenolate mofetil (MMF) used for the
treatment of lupus nephritis (LN) are based on experience in renal trans-
plant recipients. The role of therapeutic drug monitoring of mycophenolic
acid (MPA) level in managing LN remains unclear. This study aimed to inves-
tigate the relationship between MPA levels and clinical parameters in LN
patients.
Methods: We prospectively recruited LN patients who received maintenance
treatment with prednisolone and MMF during disease remission. Blood MPA
level at 1, 2, 4, 8, 10 and 12 hours (i.e. C1, C2, C4, C8, C10 and C12) after
MMF administration was measured with an enzymatic assay upon recruit-
ment and repeated at 6-month intervals for 24 months, and at occurrence
of clinically significant events. The MPA pharmacokinetics and its clinical
correlations were assessed.
Results: 51 patients were studied (mean prednisolone and MMF dosages
were 6.2  1.8 mg/d and 1284  493 mg/d respectively at baseline). C1,
C2 and C12 MPA levels were 9.9  8.7 mg/L, 8.6  6.2 mg/L,
1.9  1.4 mg/L during disease quiescence. C1, C2 and C12 MPA levels showed
a positive relationship with AUC0-12 (r Z 0.52, 0.85 and 0.77; p Z 0.004,
<0.001 and <0.001 respectively). C12 correlated negatively with hemoglo-
bin, white cell and platelet counts (r Z 0.359, 0.226, 0.20;
p Z 0.001, 0.010 and 0.024 respectively). No association exist between
C12 and anti-dsDNA, serum creatinine or 24-hour urine protein excretion
(pZ 0.53, 0.07 and 0.37 respectively). C1 and C2 did not show any relation-
ship with clinical or serological parameters. Clinically significant events
included infection in 2 patients, gastrointestinal disturbances in 3 patients,
